Figure 1.
Survival outcomes by race from the Cancer and Leukemia Group B (CALGB) trial 89803. Kaplan-Meier curves of (A) disease-free survival, (B) recurrence-free survival, and (C) overall survival of patients (n = 1206) after a median follow-up of 7.7 years.

Survival outcomes by race from the Cancer and Leukemia Group B (CALGB) trial 89803. Kaplan-Meier curves of (A) disease-free survival, (B) recurrence-free survival, and (C) overall survival of patients (n = 1206) after a median follow-up of 7.7 years.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close